Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine

NCT02959190 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02959190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 7, 2017
Completion date
August 10, 2019
Enrollment
311 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

migraine